Harold Harsch, MD
Psychiatry · Milwaukee, WINPI 1265486591
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,389 of the $7,890 with a category attached, or 81.0%. ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) accounts for 65.8% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2021 at $4,190 and has fallen 92.5% since, to $312 in 2024. Among psychiatry clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 24 payments — averaging $328.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$5K
- Sunovion Pharmaceuticals Inc.$1K
- Otsuka America Pharmaceutical, Inc.$451
- Axsome Therapeutics, Inc.$223
- AbbVie$203
- Johnson & Johnson$198
- plus $253 from 3 others
What the payments were for
- Speaking & faculty fees$6,38981%
- Food & beverage$1,43218%
- Education$691%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $5,190 |
| Sunovion Pharmaceuticals Inc. | 3 | $1,373 |
| Otsuka America Pharmaceutical, Inc. | 4 | $451 |
| Axsome Therapeutics, Inc. | 2 | $223 |
| AbbVie | 2 | $203 |
| Johnson & Johnson | 2 | $198 |
| Teva Pharmaceuticals USA, Inc. | 3 | $131 |
| Alkermes, Inc. | 1 | $105 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,890 in reported general payments places this provider in the 90th percentile of 543 psychiatry providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 17 | $51,232 |
| TrintellixVortioxetine Hydrobromide | 25 | $19,530 |
| SecuadoAsenapine | 11 | $16,370 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $13,576 |
| Imipramine Pamoate | 12 | $7,395 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 33 | $6,678 |
| FetzimaLevomilnacipran Hcl | 12 | $5,755 |
| Quetiapine Fumarate | 263 | $5,545 |
| Bupropion XlBupropion Hcl | 150 | $5,497 |
| Memantine Hcl | 179 | $4,207 |
| Duloxetine Hcl | 156 | $4,039 |
| Aripiprazole | 96 | $3,991 |
| Mirtazapine | 155 | $3,960 |
| Clozapine | 60 | $3,410 |
| Olanzapine | 110 | $2,603 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $198 | $51,23217 claims |
| Axsome Therapeutics, Inc.Auvelity | $223 | $13,57612 claims |
| AbbVieFetzima | $203 | $5,75512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 543 psychiatry providers in Wisconsin.
Other psychiatry in Milwaukee
- Thomas IlicMilwaukee$324K
- Jay WinstonMilwaukee$238K
- Joseph BurgarinoMilwaukee$111K
- Jacob BehrensMilwaukee$94K
- Selahattin KurterMilwaukee$17K
- Ajay SehgalMilwaukee$7K
- James WinstonMilwaukee$7K
- Edgar JacksonMilwaukee$5K
- Ali ArtarMilwaukee$5K
- Robert RuskiewiczMilwaukee$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.